Gonadotropin-releasing
hormone analogues
Gonadotropin-releasing
hormone analogues are used for treat-ment of advanced prostate cancer. They include:
·
goserelin
·
leuprolide
·
triptorelin.
Goserelin is absorbed slowly for the first 8
days of therapy and rapidly and continuously thereafter. After subcutaneous
injection, leuprolide is well absorbed. Neither drug’s distribution,
metabo-lism, or excretion is defined clearly.
Goserelin and leuprolide act on the male’s
pituitary gland to increase luteinizing hormone (LH) secre-tion, which
stimulates testosterone production. The peak testosterone level is reached
about 72 hours after daily administration.
With long-term administration, however, goserelin
and leuprolide inhibit LH release from the pituitary and subsequently inhibit
tes-ticular release of testosterone. Because prostate tumor cells are
stimulated by testosterone, the reduced testosterone level inhibits tumor
growth.
Triptorelin is a potent inhibitor of
gonadotropin secretion. After the first dose, levels of LH,
follicle-stimulating hormone (FSH), testosterone, and estradiol surge
transiently. After long-term con-tinuous administration, LH and FSH secretion
steadily declines and testicular and ovarian steroid production decreases. In
men, testosterone declines to a level typically seen in surgically castrat-ed
men. As a result, tissues and functions that depend on these hormones become
inactive.
Goserelin, leuprolide, and triptorelin are used for
the palliative treatment of metastatic prostate cancer. The drugs lower the
testosterone level without the adverse psychological effects of castration or
the adverse cardiovascular effects of diethylstilbe-strol.
No drug interactions have been identified with
goserelin, leupro-lide, or triptorelin. (See Adverse reactions to gonadotropin-releasing hormone analogues.)
Related Topics
Privacy Policy, Terms and Conditions, DMCA Policy and Compliant
Copyright © 2018-2023 BrainKart.com; All Rights Reserved. Developed by Therithal info, Chennai.